Teva Pharmaceutical Industries (NYSE:TEVA) Given a $13.00 Price Target by Citigroup Analysts

Share on StockTwits

Citigroup set a $13.00 price target on Teva Pharmaceutical Industries (NYSE:TEVA) in a report published on Monday, June 17th, The Fly reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also commented on TEVA. Mizuho lowered shares of Teva Pharmaceutical Industries from a buy rating to a neutral rating and dropped their price objective for the stock from $25.00 to $18.00 in a report on Wednesday, February 20th. SunTrust Banks assumed coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, March 19th. They set a hold rating and a $17.00 price objective on the stock. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a strong sell rating to a hold rating in a report on Wednesday, March 20th. Morgan Stanley lowered shares of Teva Pharmaceutical Industries from an overweight rating to an equal weight rating and set a $17.00 price objective on the stock. in a report on Wednesday, March 6th. Finally, BMO Capital Markets assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, March 28th. They issued a market perform rating and a $18.00 price target on the stock. Five investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries has an average rating of Hold and a consensus target price of $16.00.

Shares of NYSE TEVA traded up $0.11 during midday trading on Monday, reaching $9.43. 11,440,900 shares of the stock were exchanged, compared to its average volume of 13,686,958. Teva Pharmaceutical Industries has a 12 month low of $7.96 and a 12 month high of $25.96. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.66. The business’s 50-day moving average is $9.59. The stock has a market capitalization of $9.54 billion, a P/E ratio of 3.37, a price-to-earnings-growth ratio of 1.11 and a beta of 1.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business had revenue of $4.30 billion for the quarter, compared to analyst estimates of $4.38 billion. During the same period last year, the business posted $0.94 earnings per share. The firm’s quarterly revenue was down 15.2% on a year-over-year basis. Equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.27 earnings per share for the current year.

In other news, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the transaction, the vice president now directly owns 49,659 shares in the company, valued at approximately $567,105.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sol J. Barer acquired 111,000 shares of the stock in a transaction dated Monday, June 3rd. The shares were purchased at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the completion of the purchase, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The disclosure for this purchase can be found here. 0.49% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in TEVA. FMR LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 44.0% during the 4th quarter. FMR LLC now owns 35,248,665 shares of the company’s stock worth $543,534,000 after buying an additional 10,766,729 shares during the period. Norges Bank bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $146,130,000. Brahman Capital Corp. boosted its holdings in shares of Teva Pharmaceutical Industries by 67.3% during the 4th quarter. Brahman Capital Corp. now owns 12,248,106 shares of the company’s stock worth $188,866,000 after buying an additional 4,925,245 shares during the period. Menora Mivtachim Holdings LTD. boosted its holdings in shares of Teva Pharmaceutical Industries by 6,156.1% during the 4th quarter. Menora Mivtachim Holdings LTD. now owns 3,658,479 shares of the company’s stock worth $56,414,000 after buying an additional 3,600,000 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Teva Pharmaceutical Industries by 108.5% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,782,296 shares of the company’s stock worth $58,323,000 after buying an additional 1,968,077 shares during the period. 65.08% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: What is the market perform rating?

The Fly

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.